Key Points
- Director Vicki Sato sold 22,000 shares on April 1 at an average price of $9.07 for proceeds of $199,540, reducing her stake by 1.96% to 1,100,391 shares (roughly $9.98M).
- Vir reported Q4 EPS of ($0.31) vs. consensus ($0.42) and revenue of $64.07M (up 417.8% YoY), but remains unprofitable with a negative net margin of 638.88% and analysts forecasting -3.92 EPS for the year.
- The stock trades around $9.06 with a $1.26B market cap, an average analyst rating of “Moderate Buy” and a $20.44 average target, while institutional investors own about 65.3% of the shares with recent large stakes from ARCH and GSK.
Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) Director Vicki Sato sold 22,000 shares of the firm's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $9.07, for a total value of $199,540.00. Following the completion of the sale, the director owned 1,100,391 shares of the company's stock, valued at approximately $9,980,546.37. This trade represents a 1.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Vir Biotechnology Stock Up 0.4%
Shares of NASDAQ VIR opened at $9.06 on Friday. Vir Biotechnology, Inc. has a 12-month low of $4.16 and a 12-month high of $10.94. The firm's 50-day simple moving average is $8.49 and its 200 day simple moving average is $6.80. The company has a market cap of $1.26 billion, a price-to-earnings ratio of -2.87 and a beta of 1.66.
Vir Biotechnology (NASDAQ:VIR - Get Free Report) last announced its earnings results on Monday, February 23rd. The company reported ($0.31) earnings per share for the quarter, topping analysts' consensus estimates of ($0.42) by $0.11. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 49.31%. The company had revenue of $64.07 million during the quarter, compared to the consensus estimate of $19.91 million. During the same period in the previous year, the firm posted ($0.76) earnings per share. The company's revenue was up 417.8% on a year-over-year basis. On average, equities analysts expect that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several research firms have issued reports on VIR. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vir Biotechnology in a report on Monday, December 22nd. Barclays lifted their target price on Vir Biotechnology from $26.00 to $30.00 and gave the company an "overweight" rating in a research note on Tuesday, February 24th. Leerink Partners reaffirmed an "outperform" rating and set a $20.00 price target on shares of Vir Biotechnology in a research note on Thursday, February 26th. Needham & Company LLC raised their price target on Vir Biotechnology from $14.00 to $18.00 and gave the company a "buy" rating in a report on Tuesday, February 24th. Finally, HC Wainwright lifted their price objective on Vir Biotechnology from $15.00 to $20.00 and gave the stock a "buy" rating in a research report on Wednesday, March 4th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $20.44.
Read Our Latest Report on VIR
Institutional Trading of Vir Biotechnology
Several institutional investors and hedge funds have recently made changes to their positions in VIR. ARCH Venture Management LLC acquired a new stake in shares of Vir Biotechnology during the second quarter worth $65,100,000. GSK plc bought a new position in Vir Biotechnology during the fourth quarter worth about $51,562,000. Balyasny Asset Management L.P. bought a new position in Vir Biotechnology during the fourth quarter worth about $8,252,000. State Street Corp grew its position in shares of Vir Biotechnology by 18.9% during the 4th quarter. State Street Corp now owns 6,229,555 shares of the company's stock worth $37,564,000 after buying an additional 988,262 shares during the period. Finally, Millennium Management LLC increased its stake in shares of Vir Biotechnology by 129.2% in the 3rd quarter. Millennium Management LLC now owns 1,396,504 shares of the company's stock valued at $7,974,000 after acquiring an additional 787,212 shares during the last quarter. Institutional investors own 65.32% of the company's stock.
Vir Biotechnology Company Profile
(
Get Free Report)
Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.
The company's pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
